Datos del estudio Inscribiendo Actualmente

If you or your child has tested positive for type 1 diabetes related autoantibodies, we're here for you.

The next step is to get tested again for autoantibodies through the TrialNet Pathway to Prevention risk screening study. This study can identify up to five autoantibodies. JDRF, ADA, and Endocrine Society now classify having two or more of these autoantibodies as early stage type 1 diabetes (T1D).

Participating in the Pathway to Prevention risk screening study is the first step for all TrialNet prevention studies. TrialNet's prevention studies are aiming to slow or stop the disease in individuals who are in early stage T1D.

Quién puede participar

You qualify for free TrialNet risk screening if you:

  • Are between the ages of 2.5 and 45 years and have tested positive for at least one type 1 diabetes related autoantibody outside of TrialNet
  • Have not been diagnosed with diabetes


  • If you have a family member with type 1 diabetes click here

Opciones de Prueba de Detección

How to Participate

Screening is free, quick, convenient and super important. Only a small blood sample is needed.

Contact us to be connected with your nearest TrialNet location. They can help schedule an appointment at one of our many locations or they will help arrange a screening test kit at no cost.

  • In-home Test Kit: This free kit provides everything you need to collect a finger-stick blood sample from the safety of your home. You can ship it back free using FedEx contactless at home pick up.
  • Lab Test Kit: You can take this free screening kit to any Quest Diagnostics or LabCorp lab for a blood draw.

Experiencia del Participante

T1D risk screening will detect if you are in the early stages of T1D. Nearly all people that test positive for two or more diabetes-related autoantibodies will develop the disease.

Understanding Your Results

Circulado menos signo

Negativo: Menor Riesgo

No hay autoanticuerpos

No se detectaron autoanticuerpos relacionados con la diabetes (AAB).

Qué significa:

Se considera que los individuos sin autoanticuerpos tienen un riesgo bajo de desarrollar DT1. Esto no garantiza que nunca desarrollarás autoanticuerpos o DT1.

Próximos Pasos:

No hay próximos pasos que seguir en este momento. Los datos recopilados en los últimos 20 años desde la detección del riesgo de Camino a la prevención sugieren que es poco común que quienes no tienen autoanticuerpos desarrollen más tarde múltiples autoanticuerpos, por lo que TrialNet no ofrece actualmente pruebas adicionales.

Illustration of one autoantibody

One AAB Positive: Lower risk

One autoantibody (AAB) detected

What it means:

Individuals who have one AAB are at higher risk for developing T1D in their lifetime than those with no autoantibodies.

Next Steps:

There are no next steps at this time. We will let you know of any type 1 diabetes prevention trials that you might be eligible for.

Illustration of two autoantibodies

2+ AAB Positive: Early Stage T1D

Two or More AAB

Two or more autoantibodies (AAB) detected.

What it means:

Individuals who have two or more autoantibodies are already in early stage T1D. The immune system has started attacking insulin-making beta cells. The lifetime risk of developing clinical diagnosis (stage 3) approaches 100%.

Next Steps:

Come in for a study visit that will include an Oral Glucose Tolerance Test (OGTT). It will show if you have abnormal blood sugar levels and help us determine if you are eligible for a prevention study.